~~<i id='CFBE66950D'><strike id='CFBE66950D'><tt id='CFBE66950D'><pre id='CFBE66950D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：leisure time 2025-10-02 13:40:54 - browse：7

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

focus

hotspot

Wikipedia

focus

explore

StaffandvolunteersattheHungryMonkfoodpantryprepareanddistributefruitandvegetablestolocalresidentsatt

WSS

STAT Boddities: What happens to the brain when we get scared?

Resistance to opioid

SEC charges former device maker CEO with $41 million fraud

Ebola vaccine can save some who are already sick, per new study

Congress considering partial increase for doctor pay in Medicare

Bernie Sanders gets little from pharma CEOs on drug prices

hotspot

knowledge

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress must protect the remaining independent doctors

Wildfire smoke exposes gaps in outdoor worker protections

Can sheer will power keep patients alive in their dying hours?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Having children helps parents live longer, especially after age 80

Activists slam private health insurers over coverage restrictions

Medicare Advantage beneficiaries sue Humana over algorithm use

ChatGPT in medicine: STAT answers readers' burning questions

Grail spinoff by Illumina should end disastrous merger attempt

focus

Having children helps parents live longer, especially after age 80

Grail spinoff by Illumina should end disastrous merger attempt

Artificial intelligence use in health care faces greater scrutiny in 2024

Tome Biosciences co

Juul documents reveal insider tactics on political lobbying

Report cites 'urgent' need to recruit more diverse clinical trial participants

hotspot

Wikipedia

focus

explore